Physician profile
Todd C Stevens
NPI 1396793394
$6,585.80
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,909 · 2020: $390 · 2021: $1,450 · 2022: $2,616 · 2023: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $220.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $958.30 | 2019-2023 | Ozempic, Rybelsus, Saxenda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $771.32 | 2019-2023 | Synjardy, Jardiance, Ofev |
| Astrazeneca Pharmaceuticals LP | $609.65 | 2019-2023 | Breztri |
| Amarin Pharma, INC. | $435.66 | 2019-2022 | |
| Pfizer INC. | $385.59 | 2019-2022 | |
| Abbvie INC. | $372.24 | 2019-2022 | |
| Lilly USA, LLC | $366.85 | 2019-2023 | Mounjaro, Emgality, Jardiance |
| Janssen Pharmaceuticals, INC | $246.07 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $203.90 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $198.20 | 2019-2023 | |
| Amgen INC. | $184.11 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $170.73 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $169.48 | 2019-2023 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $168.96 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $163.55 | 2019-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.